SCHEMBL1240475

SCHEMBL1240475

O=C(O)C1=C(C2CCCNC2)C(=O)c2ccccc2C1=O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 1/20 0.41
FGFR2 P21802 1/20 0.41
FGFR4 P22455 1/20 0.41
FGFR3 P22607 1/20 0.41
CHRNB2 P17787 2/20 0.40
CHRNB4 P30926 2/20 0.40
CHRNA3 P32297 2/20 0.40
CHRNA4 P43681 2/20 0.40
IKBKB O14920 1/20 0.40
CHUK O15111 1/20 0.40
CSF1R P07333 1/20 0.40
BTK Q06187 1/20 0.40
JAK3 P52333 1/20 0.39
KMT2A Q03164 1/20 0.39
HTR6 P50406 1/20 0.39
HTR2A P28223 1/20 0.39
HTR2C P28335 1/20 0.39
KCNH2 Q12809 1/20 0.39
PARP1 P09874 1/20 0.38
HTR3E A5X5Y0 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28451089 0.77 HTR6 (0.38) CHRNB2CHRNB4CHRNA3CHRNA4HTR6
SCHEMBL1243097 0.75 DRD2 (0.41) FGFR1FGFR2FGFR4FGFR3HTR2A
Cadaverine Tartrate SCHEMBL17514305 0.70 JAK3 (0.50) JAK3
SCHEMBL16446714 0.70 PARP1 (0.49) CHRNB2CHRNB4CHRNA3CHRNA4IKBKB
Cadaverine Tartrate SCHEMBL17514302 0.70 JAK3 (0.50) JAK3
Cadaverine Tartrate SCHEMBL17514300 0.70 JAK3 (0.50) JAK3
SCHEMBL19465286 0.69 KMO (0.69) KMT2A
SCHEMBL4280 0.69 SLC18A3 (0.59) JAK3HTR2AHTR2CKCNH2HTR3A
SCHEMBL381572 0.69 SLC18A3 (0.59) JAK3HTR2AHTR2CKCNH2HTR3A
Benzene SCHEMBL28198364 0.69 SLC18A3 (0.59) JAK3HTR2AHTR2CKCNH2HTR3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120196852-A1 INHIBITORS OF METHIONINE AMINOPEPTIDASES AND METHODS OF TREATING DISORDERS THE JOHNS HOPKINS UNIVERSITY (US) 2012-08-02 US disclosed
WO-2011017519-A2 INHIBITORS OF METHIONINE AMINOPEPTIDASES AND METHODS OF TREATING DISORDERS THE JOHNS HOPKINS UNIVERSITY (US) 2011-02-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120196852-A1 INHIBITORS OF METHIONINE AMINOPEPTIDASES AND METHODS OF TREATING DISORDERS METAP1, METAP2, ENPEP FGFR1 4719/4885FGFR2 4815/4885FGFR4 4819/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.